Spots Global Cancer Trial Database for loss of heterozygosity
Every month we try and update this database with for loss of heterozygosity cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| The Cognitive Variability in NF1 and TSC Monozygotic Twins | NCT02436746 | Neurofibromatos... Tuberous Sclero... | - | Erasmus Medical Center | ||
| A Training Set for the HRD Model in EOC | NCT04651933 | Epithelial Ovar... BRCA Mutation Loss of Heteroz... Prognosis Platinum Resist... Homologous Reco... | Homologous reco... | 18 Years - | Peking Union Medical College Hospital | |
| Study of Skin Tumors in Tuberous Sclerosis | NCT00001975 | Tuberous Sclero... | 18 Years - 90 Years | National Institutes of Health Clinical Center (CC) | ||
| A Study of Rucaparib in Patients With Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ARIEL2) | NCT01891344 | Ovarian Cancer Epithelial Ovar... Fallopian Tube ... Peritoneal Canc... | Oral rucaparib | 18 Years - | pharmaand GmbH | |
| Study of Skin Tumors in Tuberous Sclerosis | NCT00001975 | Tuberous Sclero... | 18 Years - 90 Years | National Institutes of Health Clinical Center (CC) | ||
| A Training Set for the HRD Model in EOC | NCT04651933 | Epithelial Ovar... BRCA Mutation Loss of Heteroz... Prognosis Platinum Resist... Homologous Reco... | Homologous reco... | 18 Years - | Peking Union Medical College Hospital | |
| A Study of Rucaparib in Patients With Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ARIEL2) | NCT01891344 | Ovarian Cancer Epithelial Ovar... Fallopian Tube ... Peritoneal Canc... | Oral rucaparib | 18 Years - | pharmaand GmbH | |
| A Screening Study to Collect Samples for TAA, HLA & HLA Loss of Heterozygosity in Patients With Metastatic Solid Tumors | NCT05812027 | Head and Neck C... Cervical Cancer Non Small Cell ... Melanoma Ovarian Cancer HPV16 Related C... | Tumor and HLA P... | 18 Years - | TScan Therapeutics, Inc. | |
| ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients | NCT02855944 | Ovarian Cancer Epithelial Ovar... Fallopian Tube ... Peritoneal Canc... | Chemotherapy Rucaparib | 18 Years - | pharmaand GmbH | |
| ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients | NCT02855944 | Ovarian Cancer Epithelial Ovar... Fallopian Tube ... Peritoneal Canc... | Chemotherapy Rucaparib | 18 Years - | pharmaand GmbH | |
| Study of Skin Tumors in Tuberous Sclerosis | NCT00001975 | Tuberous Sclero... | 18 Years - 90 Years | National Institutes of Health Clinical Center (CC) | ||
| A Screening Study to Collect Samples for TAA, HLA & HLA Loss of Heterozygosity in Patients With Metastatic Solid Tumors | NCT05812027 | Head and Neck C... Cervical Cancer Non Small Cell ... Melanoma Ovarian Cancer HPV16 Related C... | Tumor and HLA P... | 18 Years - | TScan Therapeutics, Inc. |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
